Skip to main content
SP5007,785.76-0.17%DOW53,732.41-0.20%NASDAQ26,729.16-0.28%BTC$62,945.00-0.85%ETH$1,880.32-0.35%GOLD$4,432.00+0.26%OIL$82.40+1.42%
Smart Investors Daily
Sign InSign Up Free
AK

NASDAQ · AKRO

Akero Therapeutics, Inc.

Healthcare · Biotechnology

$54.65

Up+$0.00 (+0.00%)

Updated Aug 16, 2026, 8:04 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
4.5B
P/E ratio
-15.31
Dividend yield
0.00%
52-week range
— – —
Volume
11.61M
Avg. volume
2.56M

Price performance

AKRO price history

1M range · 0 trading sessions · Daily adjusted prices

AKRO does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest AKRO news

The latest Smart Investors Daily articles mentioning AKRO.

Stock researchCompany · Overview

AKRO research

Overview

Company profile and research snapshot.

Company profile

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$54.67
Implied upside
—
Analysts
—
AKRO recent ratings
DateFirmRatingTarget
Oct 10, 2025Wolfe ResearchPeer Perform—
Oct 10, 2025HC Wainwright & Co.Neutral—
Oct 9, 2025JefferiesHold—
Oct 9, 2025Canaccord GenuityHold—
Aug 4, 2025TD CowenBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Benzinga · Jul 14, 2026

NextCure To Merge With Avere Therapuetics In All-Stock Deal; NXTC Holders To Receive A Contingent Value Right For 90% Of Net Proceeds From Any Future License, Divestiture Or Monetization Of Its Pipeline Assets And Programs For Two Years; NXTC Also Announces $320M Private Placement

NextCure, Inc. (NASDAQ:NXTC) ("NextCure") and Avere Therapeutics, Inc. ("Avere"), a privately-held biotechnology company advancing oral therapies for IL-23 driven inflammatory diseases, today announced

businesswire.com · Nov 20, 2025

Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akero Therapeutics, Inc. (NasdaqGS: AKRO) to Novo Nordisk A/S. Under the terms of the proposed transaction, shareholders of Akero will receive $54.00 per share in cash, and a non-transferable Contingent Value Right entitling its holder to receive a cash payment of $6.00 per share upon full U.S.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By